Skip to main content

Table 4 Mean density and diameter of myelinated axons and thickness of their myelin sheaths

From: Enhancement of musculocutaneous nerve reinnervation after vascular endothelial growth factor (VEGF) gene therapy

  Mean density of myelinated axons/10,000 μm² (n ± SD) Axonal diameter (μm ± SD) Myelin sheath thickness (μm ± SD)
Intact MCN 138 ± 32 3.30 ± 1.23 1.20 ± 0.50
Plasmid phVEGF ETE 191 ± 46*†‡# 2.07 ± 1.20*†‡ 0.80 ± 0.30*†‡
Plasmid ETE 335 ± 45*‡ 1.72 ± 0.15*‡ 0.80 ± 0.15*‡
Vehiculum ETE 110 ± 52 1.52 ± 0.71* 0.65 ± 0.25*
Plasmid phVEGF ETS 115 ± 40†‡ 1.80 ± 0.75*†‡ 0.75 ± 0.32*
Plasmid ETS 260 ± 25*‡ 1.65 ± 0.15*‡ 0.71 ± 0.15*
Vehiculum ETS 91 ± 40 1.45 ± 0.11* 0.70 ± 0.32*
  1. * indicates statistic significance (P < 0.05) when compared with intact.
  2. † indicates statistic significance (P < 0.05) when compared with plasmid.
  3. ‡ indicates statistic significance (P < 0.05) when compared with vehiculum.
  4. # indicates statistic significance (P < 0.05) when compared with plasmid VEGF ETS.
  5. Mean density and diameter of myelinated axons as well as thickness of the myelin sheaths in the MCN of intact rats and those with end-to-end (ETE) or end-to-side (ETS) neurorrhaphy after application of plasmid phVEGF, plasmid (control) and vehiculum. Six rats were used for each group.